JP2020529440A - 糖尿病および関連する状態の処置におけるガボキサドールの使用 - Google Patents

糖尿病および関連する状態の処置におけるガボキサドールの使用 Download PDF

Info

Publication number
JP2020529440A
JP2020529440A JP2020505905A JP2020505905A JP2020529440A JP 2020529440 A JP2020529440 A JP 2020529440A JP 2020505905 A JP2020505905 A JP 2020505905A JP 2020505905 A JP2020505905 A JP 2020505905A JP 2020529440 A JP2020529440 A JP 2020529440A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
administered
hours
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020505905A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529440A5 (enExample
Inventor
マシュー・デューリング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of JP2020529440A publication Critical patent/JP2020529440A/ja
Publication of JP2020529440A5 publication Critical patent/JP2020529440A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020505905A 2017-08-04 2018-08-02 糖尿病および関連する状態の処置におけるガボキサドールの使用 Pending JP2020529440A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541260P 2017-08-04 2017-08-04
US62/541,260 2017-08-04
PCT/US2018/044973 WO2019028234A1 (en) 2017-08-04 2018-08-02 USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS

Publications (2)

Publication Number Publication Date
JP2020529440A true JP2020529440A (ja) 2020-10-08
JP2020529440A5 JP2020529440A5 (enExample) 2021-09-09

Family

ID=65230918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020505905A Pending JP2020529440A (ja) 2017-08-04 2018-08-02 糖尿病および関連する状態の処置におけるガボキサドールの使用

Country Status (10)

Country Link
US (2) US10813918B2 (enExample)
EP (1) EP3648762A4 (enExample)
JP (1) JP2020529440A (enExample)
KR (1) KR20200047557A (enExample)
CN (1) CN111201022A (enExample)
AU (1) AU2018309049A1 (enExample)
CA (1) CA3071939A1 (enExample)
IL (1) IL272414A (enExample)
MX (1) MX2020001342A (enExample)
WO (1) WO2019028234A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
KR20200069316A (ko) 2017-10-12 2020-06-16 노보 노르디스크 에이/에스 의료 요법에서의 세마글루타이드
MX2021005992A (es) 2018-11-21 2021-09-14 Certego Therapeutics Inc Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
MX2022007715A (es) 2019-12-18 2022-07-19 Ovid Therapeutics Inc Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36.
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
EP4511030A2 (en) * 2022-04-20 2025-02-26 Aclipse Two Inc. Treatment of gastrointestinal diseases
WO2025049710A1 (en) * 2023-08-29 2025-03-06 Aclipse Two Inc. Pharmaceutical composition for use in the disease treatments

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
JP2007530604A (ja) * 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
US20110015141A1 (en) * 2008-03-18 2011-01-20 Bristol-Myers Squibb Company Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof
US20130251671A1 (en) * 2010-09-28 2013-09-26 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2016102657A1 (en) * 2014-12-23 2016-06-30 Novo Nordisk A/S Alpha-cell re-generation combined with conversion to beta cells

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
EA200601853A1 (ru) * 2004-04-02 2007-02-27 Х. Лундбекк А/С Лечение нарушенной дыхательной функции
WO2006102093A1 (en) * 2005-03-18 2006-09-28 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US7635710B2 (en) 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
RS55585B1 (sr) 2006-11-22 2017-06-30 Clinical Research Associates LLC Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
WO2013024047A1 (en) * 2011-08-12 2013-02-21 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
PT3151832T (pt) 2014-06-06 2021-06-15 Ovid Therapeutics Inc Métodos para aumentar a inibição tónica e tratar a insónia secundária
JP6491679B2 (ja) 2014-06-12 2019-03-27 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｇａｂａａ受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体
AU2016295138B2 (en) 2015-07-17 2021-11-04 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US9682069B2 (en) * 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
US20180042903A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530604A (ja) * 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110015141A1 (en) * 2008-03-18 2011-01-20 Bristol-Myers Squibb Company Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof
US20130251671A1 (en) * 2010-09-28 2013-09-26 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2016102657A1 (en) * 2014-12-23 2016-06-30 Novo Nordisk A/S Alpha-cell re-generation combined with conversion to beta cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN. J. PHARMACOL., vol. 80, JPN6022030051, 1999, pages 327 - 331, ISSN: 0005006174 *

Also Published As

Publication number Publication date
WO2019028234A1 (en) 2019-02-07
US20210030728A1 (en) 2021-02-04
US11291658B2 (en) 2022-04-05
CA3071939A1 (en) 2019-02-07
US10813918B2 (en) 2020-10-27
AU2018309049A1 (en) 2020-02-27
MX2020001342A (es) 2020-08-31
US20190038606A1 (en) 2019-02-07
CN111201022A (zh) 2020-05-26
IL272414A (en) 2020-03-31
KR20200047557A (ko) 2020-05-07
EP3648762A1 (en) 2020-05-13
EP3648762A4 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
US11291658B2 (en) Use of gaboxadol in the treatment of diabetes and related conditions
US20070172525A1 (en) Anti-diabetic combinations
KR20140007247A (ko) 음식물 영향이 감소된 제어 방출 조성물
US20060141023A1 (en) Pharmaceutical compositions containing abiguanide-glitazone combination
EP3684344B1 (en) Delayed release deferiprone tablets and methods of using the same
US11813362B2 (en) Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
US20200222372A1 (en) Use of gaboxadol in the treatment of narcolepsy
TWI327469B (en) Pharmaceutical composition
KR20140045271A (ko) 제미글립틴 및 메트포르민을 포함하는 복합 제제 및 이의 제조방법
WO2016016770A1 (en) A novel modified release pharmaceutical composition of sitagliptin or pharmaceutically acceptable salt thereof
WO2016016772A1 (en) A novel modified release pharmaceutical composition of dpp-iv inhibitors or pharmaceutically acceptable salt thereof
WO2020013777A2 (en) Tablet formulations comprising metformin and sitagliptin
Mousa et al. Literature review of oral treatment of type 2 diabetes mellitus
HK40030383A (en) Use of gaboxadol in the treatment of diabetes and related conditions
US20080014261A1 (en) Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20250152527A1 (en) Therapeutic combinations of colchicine and methods of using same
US20230285369A1 (en) Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
TR2025002186T2 (tr) Evogli̇pti̇n ve metformi̇n i̇çeren oral bi̇leşi̇m formülasyonu ve bunun hazirlanmasina yöneli̇k yöntem
KR20220140343A (ko) 에보글립틴 및 메트포르민을 포함하는 경구용 복합제제 및 그의 제조방법
HK40039267A (en) Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
MX2012014757A (es) Composicion farmaceutica de una meglitinida y una tiazolidinediona o sus sales farmaceuticamente aceptables y su uso.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210729

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230307